Bioperfectus Obtains CE Mark for SARS-CoV-2 Antigen Rapid Self-Test
Posted on 05 Jan 2022
Jiangsu Bioperfectus Technologies Co., Ltd. (Shanghai, China) has obtained CE Mark for its Novel Corona Virus (SARS-CoV-2) Ag Rapid Test Kit (Self-test).
The lateral flow test is intended for non-prescription home use with self-collected nasal swab specimens. It is used to detect symptomatic individuals who are suspected of COVID-19 or asymptomatic individuals who have had contact with confirmed COVID-19 patients but do not show any symptoms. It delivers fast results within 15 minutes and is able to detect asymptomatic cases as well as remain effective in the case of variants.
The Novel Corona Virus (SARS-CoV-2) Ag Rapid Test Kit was previously available as a home test in the German and Austrian markets since May 20th, 2021. With the CE Mark, the test has received official approval following the traditional registration pathway and can now also be used in markets that have not established regulatory exemption pathways.
Related Links:
Jiangsu Bioperfectus Technologies Co., Ltd.
